


Tata India Pharma & Healthcare Fund

(An open ended equity scheme investing in Pharma and Healthcare Services Sector)

Risk-O-Meter



As on 30th June 2020

INVESTMENT STYLE

Primarily focuses on investment in at least 80% of its net assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India.

INVESTMENT OBJECTIVE

The investment objective of the scheme is to seek long term capital appreciation by investing at least 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns.

DATE OF ALLOTMENT

December 28, 2015

FUND MANAGER

Meeta Shetty (Managing Since 20-Apr-20 and overall experience of 13 years) & Rahul Singh (Managing Since 20-Apr-20 and overall experience of 23 years)

BENCHMARK

Nifty Pharma TRI

NAV

Direct - Dividend	:	12.0487
Direct - Growth	:	12.0487
Regular - Dividend	:	11.1707
Regular - Growth	:	11.1707

FUND SIZE

Rs. 240.98 (Rs. in Cr.)

MONTHLY AVERAGE AUM

Rs. 244.22 (Rs. in Cr.)

TURN OVER

Portfolio Turnover (Total)	46.56%
Portfolio Turnover (Equity component only)	46.56%

EXPENSE RATIO**

Direct	1.20
Regular	2.41

**Note: The rates specified are actual month end expenses charged as on June 30, 2020. The above ratio includes the Service tax on Investment Management Fees. The above ratio excludes, proportionate charge (out of maximum 30 bps on daily average net assets allowed) in respect sales beyond T-30 cities assets, wherever applicable.

VOLATILITY MEASURES ^ FUND BENCHMARK

Std. Dev (Annualised)	19.39	26.18
Sharpe Ratio	0.09	0.01
Portfolio Beta	0.68	1.00
R Squared	0.84	1.00
Treynor	0.76	0.11
Jenson	0.44	NA

^ Risk-free rate based on the FBIL Overnight MIBOR rate of 3.89% as on Jun 30, 2020

For calculation methodology please refer to Pg 61

MINIMUM INVESTMENT / MULTIPLES FOR NEW INVESTMENT

Rs. 5,000/- and in multiples of Re. 1/- thereafter.

ADDITIONAL INVESTMENT / MULTIPLES FOR EXISTING INVESTORS

Rs. 1,000/- and in multiples of Re. 1/- thereafter.

LOAD STRUCTURE

Entry Load : Not Applicable

Exit Load : 0.25% of NAV if redeemed on or before expiry of 3 months from the date of allotment.

Please refer to our Tata Mutual Fund website for fundamental changes, wherever applicable



PORTFOLIO

Company name	No. of Shares	Market Value Rs. Lakhs	% of Assets
Equity & Equity Related Total		23733.48	98.49
Healthcare Services			
Narayana Hrudayalaya Ltd.	382720	1025.69	4.26
Healthcare Global Enterprises Ltd.	410000	503.48	2.09
Apollo Hospitals Enterprise Ltd.	32500	438.70	1.82
Pharmaceuticals			
Sun Pharmaceutical Industries Ltd.	870100	4115.14	17.08
Dr Reddys Laboratories Ltd.	98000	3866.05	16.04
Divi Laboratories Ltd.	102500	2335.87	9.69
Lupin Ltd.	223000	2033.31	8.44
Ipca Laboratories Ltd.	95000	1590.68	6.60
Cipla Ltd.	230000	1472.58	6.11
Aurobindo Pharma Ltd.	175000	1350.48	5.60
Procter & Gamble Health Ltd.	26000	1058.17	4.39
Abbott India Ltd.	6500	1022.87	4.24
Cadila Healthcare Ltd.	217000	766.23	3.18
Natco Pharma Ltd.	100000	631.15	2.62
Alembic Pharmaceuticals Ltd.	48500	442.71	1.84
Indoco Remedies Ltd.	180000	366.84	1.52
Syngene International Ltd.	83000	332.75	1.38

Company name	No. of Shares	Market Value Rs. Lakhs	% of Assets
Other Equities ^		380.78	1.58
Repo		871.61	3.62
Portfolio Total		24605.09	102.11
Net Current Liabilities		-507.01	-2.11
Net Assets		24098.08	100.00

SIP - If you had invested INR 10000 every month

	1 Year	3 Year	5 Year	7 Year	10 Year	Since Inception
Total Amount Invested (Rs.)	120,000	360,000	NA	NA	NA	540,000
Total Value as on Jun 30, 2020 (Rs.)	143,800	450,159	NA	NA	NA	665,377
Returns	38.91%	15.09%	NA	NA	NA	9.24%
Total Value of B: Nifty Pharma TRI	149,490	414,254	NA	NA	NA	582,854
B: Nifty Pharma TRI	48.75%	9.35%	NA	NA	NA	3.35%
Total Value of AB: Nifty 50 TRI	115,000	351,928	NA	NA	NA	584,187
AB: Nifty 50 TRI	-7.67%	-1.47%	NA	NA	NA	3.45%

(Inception date :28-Dec-2015) (First Installment date : 01-Jan-2016)

Past performance may or may not be sustained in the future. Returns greater than 1 year period are compounded annualized. Dividends are assumed to be reinvested and bonus is adjusted. Load is not taken in to consideration. For SIP returns, monthly investment of equal amounts invested on the 1st day of every month has been considered.

For scheme performance refer pages 49 - 61.

*B: Benchmark, AB: Additional Benchmark

Source: MFI Explorer

Top 10 Holdings Equity


Issuer Name	% to NAV
Sun Pharmaceutical Industries Ltd.	17.08
Dr. Reddys Laboratories Ltd.	16.04
Divi Laboratories Ltd.	9.69
Lupin Laboratories Ltd.	8.44
Ipca Labs	6.60
Cipla Ltd.	6.11
Aurobindo Pharma Ltd.	5.60
Procter & Gamble Health Ltd.	4.39
Narayana Hrudayalaya Ltd.	4.26
Abbott India Ltd.	4.24
Total	82.45

Market Capitalisation wise Exposure

Large Cap	71.47%
Mid Cap	15.33%
Small Cap	13.19%

Market Capitalisation is as per list provided by AMFI.

Sector Allocation



NAV Movement

